CrossRelay platform ReDC1 cell lines Partner-facing

Human dendritic cell infrastructure for cancer immunotherapy

CrossRelay is a scalable human APC platform built to strengthen cancer immunotherapy workflows, including antigen validation, cross-presentation studies, ex vivo CTL priming, and APC-enabled immune engineering.

As immunotherapy expands across cancer vaccines, TIL therapy, CAR-T therapy, TCR-T therapy, and antigen-specific CTL programs, precise control over human antigen presentation remains a central challenge. CrossRelay addresses that bottleneck through a scalable cDC1-like APC foundation.

Work with CrossRelay See how the platform helps Learn more

Scalable APC infrastructure • ReDC1 cell lines • CD8-directed immune utility

CrossRelay platformInfrastructure layer for repeatable APC-dependent workflows

ReDC1 cell linesStandardized cDC1-like APC lines used within the platform

CD8 utilityBuilt to strengthen antigen ranking, cross-presentation, and priming

CrossRelay platform ReDC1 cell lines

Platform versus cell lines. CrossRelay is the infrastructure layer. ReDC1 cell lines are the standardized cDC1-like APC components supplied through that platform for repeatable scientific use.

Cancer immunotherapy

Current progress in cancer immunotherapy is broadening across multiple immune cell-based therapies

Cancer immunotherapy is broadening across multiple cell-based and antigen-directed modalities. Checkpoint blockade changed the field, but teaching the immune system precisely what to attack still depends on a stronger human APC layer.

Cancer vaccines

Cancer vaccines aim to direct immune recognition toward tumor antigens and to support the generation of productive anti-tumor CTLs. Their success depends heavily on dendritic-cell antigen presentation and immune instruction.

TIL therapy, CAR-T therapy, and TCR-T therapy

TIL therapy, CAR-T therapy, and TCR-T therapy represent increasingly important immune cell-based treatments. Even where T cells are expanded or engineered directly, dendritic-cell biology remains relevant to antigen spreading, immune support, and downstream immune regulation.

Antigen-specific CTLs

Many modern immunotherapy strategies ultimately seek the generation, expansion, activation, persistence, or evaluation of antigen-specific CTLs. That makes the APC layer strategically important across much of the field.

Dendritic cells

Dendritic cells bridge innate immunity and adaptive immunity in cancer immunotherapy

Dendritic cells are not merely antigen carriers. They are professional antigen-presenting cells that sense tissue danger, capture tumor antigens, integrate inflammatory signals, and determine whether T cells are activated, instructed, restrained, or ignored. In that sense, dendritic cells form the bridge between innate immunity and acquired immunity. They translate tissue-level events into antigen-specific immune responses.

Why dendritic cells remain central

Dendritic cells play essential roles in antigen uptake, antigen processing, cross-presentation on MHC class I, co-stimulation, cytokine instruction, and the orchestration of downstream cytotoxic immunity. These functions are highly relevant not only to cancer vaccines, but also to the interpretation and support of TIL therapy, CAR-T therapy, TCR-T therapy, and antigen-specific CTL workflows.

In practical terms, dendritic cells help determine whether tumor antigens become meaningful immune information. They influence whether CTLs are efficiently primed, whether anti-tumor responses expand productively, and whether immunity moves toward activation or tolerance.

Capture and process tumor antigens released from stressed or dying cancer cells.

Cross-present exogenous antigen on MHC class I to support CD8 T-cell priming.

Provide co-stimulatory signals and cytokines that shape CTL quality and persistence.

Coordinate innate sensing with adaptive immune activation across CD8 T cells, CD4 T cells, NK cells, and broader immune networks.

Regulate the balance between productive anti-tumor immunity and immune tolerance.

How CrossRelay helps

A scalable human APC platform with cDC1-like functional relevance

CrossRelay is the platform layer. ReDC1 cell lines are the standardized cDC1-like APC lines supplied through it. Together they are intended to make antigen presentation, cross-presentation, and CD8-oriented workflows more repeatable across studies.

Learn more about CrossRelay and ReDC1

CrossRelay platform ReDC1 cell lines

Primary DC workflows

Custom each time

Useful, but often complex, slow, variable, and difficult to scale across repeated studies.

→

ReDC1 cell lines
Repeatable cDC1-like APC supply
A more reusable working unit for validation, assay development, CD8 priming, and translational immunology workflows.

CrossRelay platform: infrastructure layer for repeatable APC-dependent use. ReDC1 cell lines: standardized cDC1-like APC lines used within that platform.

Platform schematic

From APC support to stronger study outputs

CrossRelay is centered on human cDC1-like cell lines that can give discovery teams a more consistent APC starting point for high-value immune workflows.

Starting point

Human cDC1-like cell lines A renewable APC source that reduces dependence on variable primary preparations.

What it supports

Antigen presentation, cross-presentation, and CD8-oriented studies Useful for teams studying antigen handling, T-cell activation logic, and APC function in a more controlled way.

What it enables

Better validation, stronger assays, and clearer translational experiments Built to help accelerate discovery work rather than force teams to rebuild APC infrastructure every time.

Ways to use the platform

One shared APC foundation, multiple ways to help your work

CrossRelay can support teams across antigen validation, assay development, ex vivo T-cell studies, and future APC-enabled research directions.

Shared foundation

CrossRelay Cell Platform

Human cDC1-like cell lines with APC, cross-presentation, and CD8-priming utility.

Validate

Evaluate targets and antigens

Support candidate antigen and neoantigen assessment in a renewable APC system.

Refine

Improve immune assays

Strengthen assay design and benchmarking with a more stable APC layer.

Prime

Support T-cell workflows

Enable ex vivo CD8 T-cell studies with stronger APC relevance.

Extend

Explore new directions

Build from the same APC chassis into broader translational and therapeutic questions.

▶

Mechanism overview

Platform media

Mechanism overview

CrossRelay can be presented through animated media that illustrates APC expansion, antigen handling, synapse formation, and CD8 activation across the platform workflow.

Why this matters

Too many discovery programs still struggle with weak APC infrastructure

Even when antigens, delivery methods, and downstream readouts improve, teams can still be constrained by APC systems burdened by complexity, timelines, variability, and logistics.

Complexitycustom setup, differentiation, and QC

Timelineslead times that can slow decisions

Variabilitydonor-sensitive performance and potency

Logisticssupply burden where access should be simpler

Primary DC workflows are complex

Conventional primary dendritic-cell workflows can behave like bespoke production instead of dependable research infrastructure.

Relevant APC states are hard to access

Many teams need cDC1-like functional relevance but lack practical access to renewable human APC systems.

Weak APC infrastructure slows programs

Researchers often spend too much effort compensating for setup instead of learning from biology and moving toward translation.

What CrossRelay provides

A platform designed to support the biology that matters

CrossRelay is the platform. ReDC1 cell lines are the standardized cDC1-like APC lines that make the platform operational in workflows requiring antigen presentation, cross-presentation, and CD8-directed immune function.

CrossRelay platform

A reusable APC infrastructure layer designed for repeatable studies rather than one-off primary-cell setup.

ReDC1 cell lines

Standardized cDC1-like APC lines intended to replace repeated custom preparation with consistent working units.

Cross-presentation and CD8 utility

Built for workflows where antigen handling, CD8 priming, and CTL-oriented interpretation matter.

Discovery-to-translation flexibility

Positioned to support discovery services today and broader translational or commercial pathways over time.

From bespoke to repeatable. The platform is designed to do for APC-dependent immunology what a digital master file does for production quality: reduce repeated custom setup and make high-value biology easier to reuse across studies.

How teams may work with CrossRelay

Support across validation, assay development, T-cell workflows, and translational studies

CrossRelay is intended to help researchers, platform teams, and translational groups move from early discovery support toward broader APC-enabled workflow and partnership models.

Validate

Antigen and target assessment

Support antigen and neoantigen studies using a renewable human APC chassis with cDC1-like functional orientation.

Refine

Immune assay development

Help strengthen APC benchmarking, potency-support, and assay-readout design with a more stable APC layer.

Prime

Ex vivo CD8 studies

Enable T-cell priming and related workflow development with stronger APC relevance.

Explore

Translational expansion

Extend from the same renewable APC chassis into broader translational and therapeutic questions.

Scientific rationale

Cross-presentation matters because the platform can help teams study it more effectively

The key value is not cross-presentation as an abstract concept. It is access to a renewable human APC platform with cDC1-like functional relevance that can help teams study high-value antigen-presentation workflows with greater consistency.

Start with a renewable APC source

Human cDC1-like cell lines provide a repeatable APC foundation instead of one-off primary preparations.

Support antigen-handling studies

The platform is built to support antigen presentation and cross-presentation workflows relevant to CD8 biology.

Study synaptic signaling more clearly

APC–T cell interaction logic can be explored with a more stable APC layer rather than an improvised one.

Move toward stronger outputs

The result is a more useful APC foundation for validation, assay development, immune engineering, and translational studies.

CD8 immunity depends on more than antigen delivery alone.

Cross-presentation is most useful when it improves actual translational decision-making.

cDC1-like functional properties are especially relevant where exogenous antigen must become actionable CD8 information.

A stronger APC layer can improve both scientific clarity and workflow repeatability.

Partnerships

Tell us what you are trying to solve

CrossRelay is here to help teams strengthen antigen validation, improve immune assays, support T-cell studies, and explore APC-dependent translational questions with a more useful human APC foundation.

Contact CrossRelay General inquiry

Target and antigen evaluation

Discuss how CrossRelay may support a specific validation or screening question.

Immune assay refinement

Explore whether a stronger APC layer could improve assay design or interpretability.

CD8 T-cell workflow support

Consider how the platform may assist ex vivo priming and related experiments.

Broader translational studies

Talk through APC-dependent questions that could benefit from a renewable human platform.